Leerink downgraded enGene (ENGN) to Market Perform from Outperform with a $2 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN:
- Leland Gershell Reiterates Hold on enGene as LEGEND Trial Efficacy Declines and Withdraws Sales Forecasts and Price Target Pending Greater Clarity
- enGene downgraded to Outperform from Strong Buy at Raymond James
- enGene downgraded to Neutral from Buy at Guggenheim
- enGene downgraded to Neutral from Overweight at Piper Sandler
- enGene downgraded to Market Perform from Outperform at Citizens